The International Biotechnology Trust (LSE: IBT) is in a long-term bull run, manager David Pinniger tells Fund Strategy. Rapidly developing technology and the continual need for new drugs are the key drivers. But it's the level of merger and acquisition activity in the sector that is particularly exciting right now. "There is a lot of money being spent at the moment, especially with the large pharma groups buying early stage companies."
The £92.3m trust trades at a 12.7% discount to its net asset value (its underlying assets), but has outperformed the FTSE World index in recent years, and returned 27.4% over three years. Most of the fund is invested in America, with 17% in Europe and 5% in Israel.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
International Biotechnology Trust top ten holdings
| Cadent | 6.1% |
| Amgen | 6% |
| Pharmasset | 5.4% |
| Teva Pharmaceutical | 5% |
| Gilead Sciences | 4.5% |
| Insulet Corp | 4.2% |
| Shire | 3.9% |
| Celgene Corp | 3.5% |
| Micromet | 3.5% |
| EUSA | 3.3% |
-
How does the Lifetime ISA work? Key LISA rulesWhat is a Lifetime ISA (LISA) and how much could the government bonus boost your savings by? We look at the perks and the pitfalls.
-
AJ Bell: a fine British fintech going cheapOpinion Don’t overlook investment platform AJ Bell, a significantly undervalued British business with an excellent financial base
